Stifel Nicolaus Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $55.00

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) had its price objective upped by Stifel Nicolaus from $35.00 to $55.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 35.84% from the stock’s previous close. Other research analysts […]

Related Keywords

Canada ,United States ,Hong Kong ,America ,Piper Sandler ,Ellen Chiniara ,Stifel Nicolaus ,Jeffreyw Albers ,Stifel Nicolau ,Royal Bank ,Tower Research Capital ,Kymera Therapeutics Inc ,Morgan Stanley ,Hong Kong Ltd ,Jpmorgan Chase Co ,Advisors Asset Management Inc ,Kymera Therapeutics ,Get Free Report ,Director Jeffrey ,Kong Ltd ,Asset Management ,Research Capital ,Kymera Therapeutics Daily ,Nasdaq Kymr ,Kymr ,Medical ,Boost Price Target ,